PHARMING GRP SP. ADRS (PHG) - Total Liabilities
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has total liabilities worth €222.86 Million EUR (≈ $260.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PHARMING GRP SP. ADRS strategic investment ratio to see how much of total assets are deployed in long-term investments.
PHARMING GRP SP. ADRS - Total Liabilities Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PHARMING GRP SP. ADRS (PHG) total assets.
PHARMING GRP SP. ADRS Competitors by Total Liabilities
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
India | Rs149.41 Billion |
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
China | CN¥255.16 Million |
|
Replimune Group Inc
NASDAQ:REPL
|
USA | $123.05 Million |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
China | CN¥678.48 Million |
|
EuroTeleSites AG
F:7YF
|
Germany | €1.69 Billion |
|
Newgen Software Technologies Limited
NSE:NEWGEN
|
India | Rs6.65 Billion |
|
Metallus, Inc
NYSE:MTUS
|
USA | $455.20 Million |
|
Shandong Nanshan Zhishang Sci-Tech Co.Ltd.
SHE:300918
|
China | CN¥1.25 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down PHARMING GRP SP. ADRS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of PHARMING GRP SP. ADRS to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHARMING GRP SP. ADRS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual total liabilities of PHARMING GRP SP. ADRS from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €222.86 Million ≈ $260.55 Million |
+24.56% |
| 2024-12-31 | €178.92 Million ≈ $209.18 Million |
-26.69% |
| 2023-12-31 | €244.07 Million ≈ $285.35 Million |
+10.36% |
| 2022-12-31 | €221.16 Million ≈ $258.56 Million |
+8.20% |
| 2021-12-31 | €204.40 Million ≈ $238.96 Million |
-- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more